BR112021022347A2 - Processos e intermediários para a preparação de um inibidor de btk - Google Patents

Processos e intermediários para a preparação de um inibidor de btk

Info

Publication number
BR112021022347A2
BR112021022347A2 BR112021022347A BR112021022347A BR112021022347A2 BR 112021022347 A2 BR112021022347 A2 BR 112021022347A2 BR 112021022347 A BR112021022347 A BR 112021022347A BR 112021022347 A BR112021022347 A BR 112021022347A BR 112021022347 A2 BR112021022347 A2 BR 112021022347A2
Authority
BR
Brazil
Prior art keywords
preparation
intermediates
processes
btk inhibitor
btk
Prior art date
Application number
BR112021022347A
Other languages
English (en)
Other versions
BR112021022347A8 (pt
Inventor
Andras Horvath
Yi Chen Cheng
Jinxiong Su
James Pye Philip
Shuo Wang
Albert Wagschal Simon
Yuanyuan Yuan
Original Assignee
Janssen Pharmaceutica Nv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Janssen Pharmaceutica Nv filed Critical Janssen Pharmaceutica Nv
Publication of BR112021022347A8 publication Critical patent/BR112021022347A8/pt
Publication of BR112021022347A2 publication Critical patent/BR112021022347A2/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
    • Y02P20/00—Technologies relating to chemical industry
    • Y02P20/50—Improvements relating to the production of bulk chemicals
    • Y02P20/55—Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)

Abstract

processos e intermediários para a preparação de um inibidor de btk. a presente invenção refere-se a um processo para a preparação determinados intermediários, por exemplo, um processo para a preparação de um composto de fórmula (i); em que r1, r2 e x1 são conforme definidos na descrição, sendo que seus intermediários e processos são úteis na preparação de um inibidor de btk, como ibrutinibe.
BR112021022347A 2019-05-21 2020-05-20 Processos e intermediários para a preparação de um inibidor de btk BR112021022347A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
CN2019087823 2019-05-21
PCT/EP2020/064123 WO2020234381A1 (en) 2019-05-21 2020-05-20 Processes and intermediates for preparing a btk inhibitor

Publications (2)

Publication Number Publication Date
BR112021022347A8 BR112021022347A8 (pt) 2021-12-28
BR112021022347A2 true BR112021022347A2 (pt) 2022-01-04

Family

ID=70857160

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112021022347A BR112021022347A2 (pt) 2019-05-21 2020-05-20 Processos e intermediários para a preparação de um inibidor de btk

Country Status (11)

Country Link
US (1) US20220204516A1 (pt)
EP (1) EP3972977A1 (pt)
JP (1) JP2022533747A (pt)
KR (1) KR20220011668A (pt)
CN (1) CN113874378A (pt)
AU (1) AU2020278162A1 (pt)
BR (1) BR112021022347A2 (pt)
CA (1) CA3135240A1 (pt)
IL (1) IL288154A (pt)
MX (1) MX2021014246A (pt)
WO (1) WO2020234381A1 (pt)

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
LT2530083T (lt) * 2006-09-22 2016-09-26 Pharmacyclics Llc Brutono tirozinkinazės inhibitoriai
MA33152B1 (fr) 2009-03-31 2012-03-01 Boehringer Ingelheim Int Dérivés 1-hétérocyclyl-1, 5-dihydro-pyrazolo [3, 4-d] pyrimidin-4-one et leur utilisation en tant que modulateurs de pde9a
CN103121999A (zh) * 2012-08-29 2013-05-29 苏州迪飞医药科技有限公司 一种酪氨酸激酶抑制剂pci-32765的合成方法
SG11201507595XA (en) 2013-03-15 2015-10-29 Janssen Pharmaceutica Nv Processes and intermediates for preparing a medicament
US9156847B2 (en) * 2013-03-15 2015-10-13 Janssen Pharmaceutica Nv Processes and intermediates for preparing a medicament
MA41350A (fr) 2015-01-14 2017-11-21 Janssen Pharmaceutica Nv Synthèse d'un inhibiteur de la tyrosine kinase de bruton

Also Published As

Publication number Publication date
KR20220011668A (ko) 2022-01-28
CN113874378A (zh) 2021-12-31
CA3135240A1 (en) 2020-11-26
WO2020234381A1 (en) 2020-11-26
JP2022533747A (ja) 2022-07-25
IL288154A (en) 2022-01-01
MX2021014246A (es) 2022-01-06
AU2020278162A1 (en) 2021-11-18
US20220204516A1 (en) 2022-06-30
EP3972977A1 (en) 2022-03-30
BR112021022347A8 (pt) 2021-12-28

Similar Documents

Publication Publication Date Title
BR112018001400A2 (pt) compostos, processo para a síntese dos compostos, composição, utilização de um composto, método para o combate dos fungos e sementes
UY30662A1 (es) Método de cristalizacion discontinuo para cristalizar un anticuerpo anti-htnfalfa, cristales de anticuerpo obtenido por dicho método, composiciones que los conitenen y aplicaciones
BR112018075939A2 (pt) compostos heterocíclicos como antibacterianos
BR112018014536A2 (pt) derivados de amônio, um processo para sua preparação e composições farmacêuticas contendo os mesmos
DOP2019000087A (es) Compuestos químicos
BR112017028322A2 (pt) compostos, processo para a produção de compostos i, para a produção de compostos ii dos compostos iii e para a produção de compostos iii, compostos intermediários v e utilização dos compostos i
BR112017007969A2 (pt) método para produção de e-caprolactama
BR112022005472A2 (pt) Inibidores heterocíclicos de monoacilglicerol lipase (magl), seus usos, processo de fabricação e composição farmacêutica
BR112016008354A2 (pt) processo de preparação de alquilaluminoxanos por meio da reação de alquilalumínio com um álcool alílico substituído da fórmula, produto que pode ser obtido por meio do processo, e, uso do produto
BR112018073490A2 (pt) 6.7.beta-epóxidos esteroides como intermediários químicos
BR112022006052A2 (pt) Processo para a preparação de protioconazol
BR112014014604A2 (pt) processo para a preparação de um composto, e, composto isolado e purificado
BR112023018655A2 (pt) Compostos antibacterianos
BR112019005886A2 (pt) tratamento com água de material lipídico
BR112023018654A2 (pt) Compostos antibacterianos
BRPI0816830A8 (pt) Processo para a preparação de derivados de 2,2-diflúor-etilamina por hidrogenação de amida
BR112022002815A2 (pt) Método para preparar 2-(fenilimino)-3-alquil-1,3-tiazolidin- 4-onas
BR112021022347A2 (pt) Processos e intermediários para a preparação de um inibidor de btk
BR112022009688A2 (pt) Processo para a síntese de (3-cloro-2-piridil)hidrazina
CL2019000074A1 (es) Método de producción de cristal de compuesto de uracilo.
BR112022002060A2 (pt) Síntese de escala de processo de um inibidor de calicreína de plasma
BR112015014440A2 (pt) processo para a produção de uma solução aquosa purificada de peróxido de hidrogênio
BR112022005068A2 (pt) Compostos antibacterianos de 4-quinolinona
BR112022005449A2 (pt) Compostos antibacterianos
BR112013004546A2 (pt) processo para produção de tmhq.